Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Lol

<< Previous

Bullboard Posts

Next >>

Comment by Yellowknifer69on Oct 21, 2022 10:47am

186 Views

Post# 35038760

RE:Lol

Hello and good morning ATE Longs:

While the stock is definitely heading in the wrong directions, it obvious that ATE is following broader market trends. Nobody is spending money at the moment.

But then you have losers, like Stutters, that can do nothing except make fun of others. it is sad to have to put him on the IGGY list but just so sick of listening to his drivel.

Take ccccare sttttutters - I miss you already!

Yellowknifer

<< Previous

Bullboard Posts

Next >>

Debt-free cannabis company set for next stage of growth